Elinzanetant vs HRT: What Your Doctor Isn’t Telling You About the New Hot Flash Drugs [2026]

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN • U.S. Navy veteran (13 years) • Author, The Book of Hormones • Founder, Gaya Wellness

Published April 16, 2026 • Reviewed by Dr. Shweta Patel, MD, FACOG

I’ve been watching this unfold in my practice for the last six months.

A woman comes in. She’s 51. She’s drenched every night at 2 a.m. She’s had hot flashes intense enough to leave meetings. She’s exhausted. And she tells me her primary care doctor — or more often, a nurse practitioner at a walk-in clinic — just prescribed her a new pill called Lynkuet. Or Veozah. Non-hormonal, they told her. Safer than HRT, they implied.

Nobody ran her hormones. Nobody asked about her cycle history, her family history, or her cardiovascular risk. Nobody walked her through the fact that the FDA just pulled the scariest warning off hormone therapy after two decades of it being misapplied. They just wrote her a script for a new $550-a-month drug that treats one symptom.

Let me be clear: the new drugs are real medicine. I prescribe elinzanetant in the right clinical situations. It’s genuinely useful for women who cannot take estrogen. But “cannot take estrogen” and “hasn’t been offered estrogen” are two completely different categories of women. And right now, the second group is being funneled straight into the first.

What Just Changed: The New Non-Hormonal Hot Flash Drugs

Two drugs in this class are now on the U.S. market. They work differently than anything we had before.

Fezolinetant (Veozah) was approved by the FDA in May 2023. It was the first neurokinin receptor antagonist cleared for menopausal vasomotor symptoms. It blocks the NK-3 receptor in the hypothalamus. In its Phase 3 SKYLIGHT trials, it reduced hot flash frequency by approximately 60%.

Elinzanetant (Lynkuet), from Bayer, was approved by the FDA in October 2025. It’s the next generation — a dual neurokinin-1 and neurokinin-3 receptor antagonist. It blocks two receptors instead of one. In the Phase 3 OASIS program, it reduced moderate-to-severe vasomotor symptoms by approximately 73-74% at 12 weeks, with sustained effect over 52 weeks.

Both are oral, once-daily pills. Both are non-hormonal. Both were designed for women who genuinely can’t or don’t want to take estrogen. That’s the legitimate clinical lane — and it’s an important one.

But here’s the problem: pharmaceutical marketing doesn’t stay in its lane. The messaging being rolled out in 2026 is positioning these drugs as a general alternative to hormone replacement therapy — including for women who should be on hormones.

How These Drugs Actually Work (Plain English)

This is the part nobody explains in a 10-minute visit, so let me explain it the way I would to a patient.

There’s a cluster of neurons deep in your brain called KNDy neurons (pronounced “candy”). They sit in the hypothalamus, and they’re part of your body’s thermostat. When estrogen is plentiful, these neurons behave themselves. They stay the right size. They signal the right way. Your body temperature stays stable.

When estrogen declines during perimenopause and menopause, those KNDy neurons hypertrophy — they literally get bigger. They start firing more aggressively. That hyperactivity is what causes a hot flash: your brain misreads your normal body temperature as overheating and triggers a full thermoregulatory response — vasodilation, sweating, heart pounding.

Neurokinin receptor antagonists don’t restore estrogen. They tell those hyperactive neurons to quiet down. Fezolinetant blocks NK-3 receptors. Elinzanetant blocks both NK-1 and NK-3, which is part of why it shows broader benefits on sleep and mood in addition to hot flashes.

This is genuinely clever pharmacology. It’s targeted. It works. And for a woman who legitimately cannot have estrogen, it’s a breakthrough.

But notice what it doesn’t do. It doesn’t restore bone mass. It doesn’t improve insulin sensitivity. It doesn’t reduce visceral fat accumulation. It doesn’t protect cardiovascular function. It doesn’t address the dozens of other consequences of losing the master metabolic regulator that is estrogen. It just quiets one brain circuit.

The Data: What the OASIS and SKYLIGHT Trials Actually Show

Here are the numbers, because in my practice we make decisions on data, not vibes.

Elinzanetant — OASIS 1 and 2 trials (published in JAMA, August 2024): Two randomized, double-blind Phase 3 trials enrolled 796 postmenopausal women across the U.S., Canada, Europe, and Israel. At week 12, 71-75% of women on elinzanetant achieved at least a 50% reduction in moderate-to-severe hot flash frequency, compared to placebo. Treatment-emergent adverse events were generally mild to moderate — most commonly headache and fatigue. (Source: PubMed)

Elinzanetant — OASIS 3 trial (published in JAMA Internal Medicine, September 2025): A 52-week study of 628 postmenopausal women showed a 73% reduction in VMS frequency and severity at 12 weeks, with no signals of hepatotoxicity, endometrial hyperplasia, or meaningful bone density changes. Treatment-related adverse events: 30.4% on elinzanetant vs 14.6% on placebo. Most common: somnolence, fatigue, headache. (Source: PubMed)

Fezolinetant — SKYLIGHT trials: Approximately 60% reduction in hot flash frequency across diverse populations. But this is the part that matters: on December 16, 2024, the FDA added a boxed warning to fezolinetant for rare but serious liver injury. Women on Veozah now require liver function testing at baseline, monthly for the first three months, and again at months 6 and 9. A boxed warning is the most serious warning the FDA issues. It’s the same category that was on hormone therapy for two decades — the one the FDA just removed from HRT.

Sit with that for a second. The drug being marketed as the “safer” alternative to hormones now carries a boxed warning. The drug it’s supposedly safer than doesn’t.

Elinzanetant vs Fezolinetant vs HRT: Side-by-Side

This is what the comparison actually looks like in 2026:

Look at that cost row one more time. The drug being positioned as the safer, simpler option costs roughly 10 times what generic transdermal estradiol costs — and treats one symptom instead of addressing the hormonal deficiency underneath.

Who These Drugs Are Actually For

This is the clinical reality. The legitimate use case for neurokinin antagonists is specific, and it matters:

• Breast cancer survivors and women on adjuvant endocrine therapy. Women on tamoxifen or aromatase inhibitors are often deep in induced menopause with brutal vasomotor symptoms and no option for systemic estrogen. The OASIS 4 trial specifically enrolled this population. This is exactly where these drugs shine.
• Women with hormone-sensitive cancer history where the oncology team has advised against estrogen.
• Women with a history of VTE or stroke where even transdermal estrogen carries unacceptable risk after full evaluation.
• Women with active liver disease — though here elinzanetant may be preferable to fezolinetant given the hepatotoxicity signal on the latter.
• Women who have tried appropriate HRT and cannot tolerate it, or who have a well-informed, physician-supported preference against hormones.

These are real patients. They deserve options that didn’t exist three years ago. The approval of elinzanetant in October 2025 is a meaningful advance in menopause care for them.

That is not most women with hot flashes.

Who’s Going to Get Prescribed These Instead — And Why That’s a Problem

Here’s the pattern I’m watching play out. A woman in her late 40s or early 50s walks into a primary care office with hot flashes and disrupted sleep. The provider has 12 minutes. She doesn’t specialize in menopause. She remembers something about hormone therapy being risky. She’s seen the Bayer rep or the Astellas email. A prescription for Lynkuet or Veozah feels clean, low-risk, defensible.

The patient walks out with a $500-$550 per month prescription, no hormonal workup, no cardiovascular risk assessment, no conversation about what she’s actually losing when estrogen drops.

What did she miss?

• Bone. Estrogen loss accelerates bone resorption. Without HRT or an equivalent bone-protective strategy, bone density drops every year past menopause and lifetime fracture risk climbs. Neurokinin antagonists do nothing for bone.
• Cardiovascular function. The 2016 ELITE trial in the New England Journal of Medicine showed that estradiol started early in menopause slowed progression of subclinical atherosclerosis. That window — the decade after menopause — is when those benefits are achievable. Missing it has consequences no NK-antagonist can undo.
• Metabolic health. Estrogen drives insulin sensitivity, body composition, and fat distribution. Its loss fuels insulin resistance, visceral fat, and muscle loss — the core of menopausal weight gain. NK-antagonists don’t touch any of it.
• Cognition and mood. Estrogen supports serotonin receptor function; progesterone supports GABA-mediated calming. Countless women are handed antidepressants in perimenopause when the real issue is hormonal — I’ve written about why that’s a clinical failure. An NK-antagonist doesn’t address it either.
• Genitourinary symptoms. Vaginal dryness, painful sex, urinary urgency. Topical vaginal estrogen is the standard of care. Systemic NK-antagonists don’t help here.

When a woman with no contraindications to estrogen is given a neurokinin antagonist instead of HRT, she’s trading a cheap, evidence-based treatment that addresses the underlying deficiency for an expensive, symptom-only drug. That’s not patient choice — that’s the limits of a rushed system, dressed up as progress.

The FDA Decision Nobody Explained to You

In November 2025, the FDA announced it was removing the black box warning from menopausal hormone therapy products. This was major news. You may not have heard about it, because the companies selling non-hormonal alternatives didn’t exactly put it in their marketing emails.

That black box — the scariest warning the FDA issues — had sat on hormone therapy since the early 2000s, after the Women’s Health Initiative (WHI) findings appeared to link HRT to increased risks of breast cancer, heart disease, and stroke. For two decades, that warning kept millions of women off hormone therapy and made entire generations of physicians afraid to prescribe it. Menopause became a symptom to be endured, not a hormonal deficiency to be treated.

The problem? The WHI data was never what it was made out to be. The average age in the study was 63. Many women were more than a decade past menopause. The hormone preparations used — oral conjugated equine estrogens and medroxyprogesterone acetate — aren’t what we use now. When the data was reanalyzed for women who started HRT before age 60 or within 10 years of menopause, the risk profile looked entirely different. In that population, HRT is associated with reduced all-cause mortality, reduced cardiovascular disease, and protection against osteoporotic fracture.

The November 2025 decision is the regulatory catch-up to decades of reanalysis. The system finally correcting a 20-year overcorrection.

And the timing matters. One month before the FDA lifted the HRT warning, they approved elinzanetant. The same month they added a boxed warning to fezolinetant a year earlier. We are at a genuine inflection point — and for most women, the inflection is back toward HRT, not away from it.

How to Tell If You Should Be on HRT First

Before you accept a prescription for a non-hormonal VMS drug, these are the questions that should have been asked:

1. Have you had a full hormonal evaluation?
Not a single FSH level. A comprehensive panel reflecting where you actually are in the transition — estradiol, progesterone, testosterone, thyroid, metabolic markers. Without it, you don’t know whether HRT is a fit.

2. Have you had a cardiovascular risk assessment?
Blood pressure, lipid panel, clot history. This determines whether systemic estrogen is appropriate and which delivery method (transdermal is generally preferred when any cardiovascular considerations exist).

3. Do you have an actual contraindication to estrogen?
Active breast cancer, certain hormone-sensitive cancers, recent VTE, active liver disease, unexplained vaginal bleeding. If yes — non-hormonal options make sense. If no, the conversation shouldn’t default there.

4. Have the other consequences of estrogen loss been assessed?
Bone density. Metabolic markers. Mood and cognitive symptoms. Genitourinary symptoms. A drug that only treats hot flashes is only half an answer.

5. Do you understand the updated HRT evidence?
If your decision against HRT is “I heard it causes breast cancer” — that’s not informed consent. The evidence has moved. Your physician should walk you through where it stands.

If you haven’t had this conversation, you haven’t been offered a real choice.

What Physician-Led Menopause Care Actually Looks Like

This is exactly why we built Hormonal Agency™ at Gaya Wellness — the antidote to the vending-machine telehealth model that’s going to push millions of women toward expensive symptom-only prescriptions over the next two years.

Here’s what the program looks like:

• Agency Rx ($149/mo): Access to a board-certified OB/GYN, physician-guided prescribing of bioidentical HRT or non-hormonal options when indicated, and messaging support between visits.
• Complete ($249/mo): Comprehensive lab panel including estradiol, progesterone, testosterone, thyroid, and metabolic markers. Protocol built on your actual biochemistry, not a template.
• Total ($349/mo): Full 50+ biomarker workup, quarterly lab recheck, DEXA recommendation, and ongoing physician oversight.

Not sure where you fit? Start with the 2-minute hormone quiz. It takes less time than a telehealth intake form.

The point isn’t that non-hormonal drugs are bad — they’re an important addition to the toolkit for women who need them. The point is that for most women, they should be the second conversation, not the first prescription.

You Haven’t Failed. The System Gave You the Wrong First Option.

If you’ve been handed a prescription for Lynkuet or Veozah without a hormonal workup — that’s not your fault. You walked into a system faster at writing prescriptions than at asking the right questions. You trusted a professional. That’s reasonable.

But the next conversation is yours to have. You can ask for the hormonal panel. You can ask why HRT was ruled out — and whether it was actually ruled out, or just skipped. You can ask what your bone density is doing, what your cardiovascular risk looks like, what your metabolic markers say. You can find a physician who will answer those questions before writing anything.

The new drugs are a real advance. For the right women. For everyone else, they’re the system’s latest way of treating menopause as a collection of symptoms rather than what it actually is: a hormonal transition that deserves a hormonal conversation.

Your body changed. Your strategy needs to change with it — and that strategy should start with your hormones.

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN, U.S. Navy veteran, and founder of Gaya Wellness. Dr. Patel leads physician-managed programs in medical weight loss, hormone optimization, and longevity medicine for women in midlife and beyond.